comparemela.com

Page 8 - Intravenous News Today : Breaking News, Live Updates & Top Stories | Vimarsana

FDA Approves Nivolumab for Resected Stage IIB/C Melanoma

The new approval expands the melanoma indication for nivolumab to earlier-stage disease.

Bristol myers squibbDrug administrationMyers squibbMalignant melanomaSkin cancerAlignant skin neoplasmDisease recurrenceSentinel lymph nodeUs food and drug administrationNited states food and drug administrationIntravenous ivLymph nodesOrphan drugsPain managementPain management

FDA Approves Intravenous Formulation of Secukinumab

This new route of administration is expected to become available during the fourth quarter of 2023.

Philipj measeChristy siegelUniversity of washingtonSchool of medicineDrug administrationSwedish medical centerPsoriatic arthritisIntravenous ivAnkylosing spondylitisBiologic therapyOint inflammationTnf alphaTumor necrosis factor alphaUmor necrosis factor tnfHealthcare and medical technologyEalth and medical tech

FDA Approves First Tocilizumab Biosimilar

Tocilizumab-bavi (Tofidence) will offer a lower-cost option for patients with autoimmune conditions, the drug manufacturer, Biogen, stated.

Actemra genentechIan henshawTyenne fresenius kabiEuropean commissionDrug administrationFresenius kabiBiologic therapyUs food and drug administrationNited states food and drug administrationIntravenous ivRheumatoid arthritisOint inflammation

FDA Approves Subcutaneous Vedolizumab for Moderate to Severe UC

Data from the VISIBLE 1 trial showed more patients receiving subcutaneous vedolizumab achieved clinical remission, mucosal healing, durable clinical response, durable clinical remission, and corticosteroid-free clinical remission compared to those receiving placebo.

Alimentiv bruce sandsDrug administrationSubcutaneous administration of takedaPbruce sandsEuropean gastroenterology weekBrandon monkBusiness unitSubcutaneous administrationMaintenance therapySeverely active ulcerativeVedolizumab subcutaneouslyInvestigational subcutaneous formulationVedolizumab achievesMaintains clinical remissionMucosal healingUlcerative colitis

Could Your Patients Benefit? New Trials in Lung Cancer

Several trials in lung cancer have opened their doors recently perhaps one of your patients could benefit.

United statesResearch centerNational cancer instituteGabrail cancerFast track designationLung cancerUng carcinomaAncer lungNon small cell lung cancerSmall cell lung cancerAlignant neoplasiaBiologic therapyIntravenous ivTyrosine kinase inhibitor

vimarsana © 2020. All Rights Reserved.